Hopes Dashed for Aducanumab in Alzheimer ' s Disease Hopes Dashed for Aducanumab in Alzheimer ' s Disease

The phase 3 ENGAGE and EMERGE trials, which were assessing the novel amyloid-B-targeting agent aducanumab for Alzheimer ' s-related dementia, have been discontinued due to futility.Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news